Gilead Sciences (NASDAQ:GILD) Director Sells $617,500.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the transaction, the director owned 8,920 shares in the company, valued at $1,101,620. The trade was a 35.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jeffrey Bluestone also recently made the following trade(s):

• On Friday, November 28th, Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $135.93 on Friday. The firm has a market capitalization of $168.65 billion, a P/E ratio of 21.07, a P/E/G ratio of 0.69 and a beta of 0.33. The firm’s 50-day moving average price is $123.98 and its 200-day moving average price is $118.62. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 1-year low of $92.26 and a 1-year high of $136.30.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same period in the previous year, the company posted $2.02 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently added to or reduced their stakes in the company. GoalVest Advisory LLC lifted its position in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Corundum Trust Company INC bought a new position in shares of Gilead Sciences during the third quarter valued at approximately $26,000. Financial Consulate Inc. lifted its holdings in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the last quarter. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $27,000. Finally, BOCHK Asset Management Ltd purchased a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $31,000. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on GILD shares. Truist Financial started coverage on shares of Gilead Sciences in a report on Monday, November 24th. They set a “buy” rating and a $140.00 price objective for the company. Needham & Company LLC lifted their price target on Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. HSBC increased their price objective on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Wall Street Zen downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday. Finally, Wolfe Research reissued an “outperform” rating and issued a $150.00 price target on shares of Gilead Sciences in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $133.52.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.